New technologyNovel Ultrafiltration Technique for Blood Conservation in Cardiac Operations
Section snippets
Technology
The novel HemoSep technology was created at Strathclyde University (Glasgow, United Kingdom), and the clinical evaluation was conducted in patients who were treated at University of Kirikkale-Turkey (Golbasi-Ankara, Turkey). The study was approved by the University of Kirikkale-Turkey Institutional Ethics Board for Clinical Research (Ref No. 2011/0588) on Jan 12, 2011.
Technique
Before blood was introduced into the HemoSep bag, the system was first primed using 150 mL normal saline solution. The bag was then gently rotated by hand to ensure that the polycarbonate control membrane was adequately wetted, until the priming liquid was entirely adsorbed into the superadsorber pad. Once the volume of blood was introduced, the inlet and outlet tubes were clamped and the bag was placed into the orbital shaker chamber. The shaker was switched on and orbital, periodic
Clinical Experience
The preoperative evaluation of patients is reported in Table 1. The mean amount of processed blood was 775 ± 125 mL at the end of 40 minutes. The clinicians reported no technical failures with the HemoSep device and were pleased with its ease of use and overall performance.
No significant difference in plasma free hemoglobin, international normalized ratio, activated clotting time, and partial thromboplastin time levels were demonstrated. Table 2 presents the data before and after HemoSep
Comment
The objective of the HemoSep development was to design a hemoconcentration technology that does not require centrifugation and associated blood transfer steps and can be used without the need for highly trained technical personnel. An additional benefit of the HemoSep technology is that it produces a gelatinous waste product, essentially plasma in a gel matrix, which is safer and easier to dispose of than the large volumes of fluid associated with the more common centrifugation processes.
Our
Disclosures and Freedom of Investigation
The study was funded by University of Kirikkale Research Fund, Turkey (2011/223) and Brightwake Ltd., Nottingham, United Kingdom. The authors were free from outside interests in controlling the design of the study, acquisition of data, collection, analysis and interpretation of data and have freedom to fully disclose all results. The devices were provided at no charge.
References (10)
- et al.
2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines
Ann Thorac Surg
(2011) - et al.
Comparative study of cell saver and ultrafiltration nontransfusion in cardiac surgery
Ann Thorac Surg
(1990) - et al.
Stored packed red blood cell transfusion upregulates inflammatory gene expression in circulating leukocytes
Ann Surg
(2007) - et al.
Levels of inflammatory markers in the blood processed by autotransfusion devices during cardiac surgery associated with cardiopulmonary bypass circuit
Perfusion
(2002) - et al.
Blood transfusion is associated with increased resource utilization, morbidity and mortality in cardiac surgery
Ann Card Anaesth
(2008)
Cited by (0)
Disclaimer
The Society of Thoracic Surgeons, the Southern Thoracic Surgical Association, and The Annals of Thoracic Surgery neither endorse nor discourage use of the new technology described in this article.